Molnupiravir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Molnupiravir
- Molecular weight
- 329.31
- Structure (SMILES)
- CC(C)C(=O)OC[C@H]1O[C@@H](n2cc/c(=N\O)[nH]c2=O)[C@H](O)[C@@H]1O
- .BETA.-D-N4 HYDROXYCYTIDINE-5'-ISOPROPYL ESTER
- beta d n4 hydroxycytidine 5 isopropyl ester
- eidd 1931 isopropyl ester
- Eidd 1931-isopropyl ester
- eidd 2801
- EIDD-1931 ISOPROPYL ESTER
- Eidd-2801
- EIDD-2801
- mk 4482
- MK-4482
- molnupiravir
- Molnupiravir
- Molnupiravir (Esperavir)
- molnupiravir [INN]
- MOLNUPIRAVIR [JAN]
- MOLNUPIRAVIR [USAN]
- Molnupiravir [WHO-DD]
- Molnupiravir 200 mg
- Molnupiravir 400 mg
- Molnupiravir 800 mg
- molnupiravir inn
- molnupiravir jan
- molnupiravir usan
- molnupiravir who dd
- CAS registry numbers
- 2492423-29-5
- ChEMBL ID
- CHEMBL4650320
- InChIKey
- HTNPEHXGEKVIHG-QCNRFFRDSA-N
- PubChem compound IDs
- 145996610
- RxNorm IDs (RxCUI)
- 2587901
- FDA ingredient codes (UNII)
- YA84KI1VEW
- J05A
- J05AB18
Sources for recorded values
- Status
- application_withdrawn
- Status date
- 21 Jun 2023
- Approved indications
- Treatment of coronavirus disease 2019 (COVID-19).
- Product number
- EMEA/H/C/005789
- Authorisation holder
- Merck Sharp & Dohme B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- COVID-19 virus infection
European medicines record
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- molnupiravir
- Type
- Synthetic organic
- Drug name stem
- -vir; -vir
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Mechanism
- RNA disrupting agent
- Action type
- DISRUPTING_AGENT
- Target
- RNA
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Virus Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Influenza, Human
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001577
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100163
- Highest recorded phase
- 3
Reported adverse events
- Event
- torsade de pointes
- Reports
- 2
- Reporting signal score
- 12.1107
- NCT04381936
- NCT04730206
- NCT04392219
- NCT04405570
- NCT04405739
- NCT04575584
- NCT04575597
- NCT04746183
- NCT04939428
- NCT05041907
- NCT05459532
- NCT05595824
- NCT05386589
- NCT05386758
- NCT05559905
- NCT05648448
- NCT05818124
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 4
- Polar surface area
- 146.37
- Calculated partition coefficient (ALogP)
- -1.72
- Calculated partition coefficient (XLogP)
- -0.8
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 23
- Molecular formula
- C13H19N3O7
- Monoisotopic mass
- 329.12229995
- Natural product
- No
- Recorded assays
- 47
- Active assays
- 17
Active assay types
- Confirmatory
- Antiviral Agents
Related records
Trials (27)
- A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
- A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
- A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
- A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)
- Adaptive Dengue Antiviral Platform Trial
- AGILE (Early Phase Platform Trial for COVID-19)
- Assessing Antiviral Treatments in Early Symptomatic RSV
- COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
- Effectiveness and Safety of New Oral Antivirals for COVID-19
- Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
- Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
- Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
- Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
- Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
In development for (7)
- COVID-19 Phase 3
- Influenza Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Respiratory syncytial virus infectious disease Phase 2
- Severe acute respiratory syndrome Phase 3
- Viral infectious disease Phase 3